28 June 2018 | News
As part of the collaboration, a C-Trap optical tweezers-fluorescence microscope has been installed at the University of Cambridge.
Image credit- dynamicbusiness.co.au
LUMICKS, a world leader in dynamic single-molecule analysis, has partnered with AstraZeneca and the University of Cambridge Biochemistry Department to form the 'centre of Excellence for Dynamic Single-Molecule Analysis for Accelerated Drug Discovery and Biology', the first of its kind worldwide.
As part of the collaboration, a C-Trap optical tweezers-fluorescence microscope has been installed at the University of Cambridge and will be used by AstraZeneca, University of Cambridge research groups and LUMICKS, to provide new insights in biology and early-stage drug discovery research.
LUMICKS' technology allows for analysis of complex dynamic details related to the behavior and interaction of single molecules, allowing the centre to investigate both the fundamental cause of diseases and potential for drug optimization.
This collaboration aims to generate data that will validate the use of dynamic single-molecule technology for biomedical and pharmaceutical research and potential applications for accelerating drug discovery.